Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Alverine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.82 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.82 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.82 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.82 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.82 |
| ▸ | DRD1 | P21728 | 1/20 | 0.82 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.82 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.82 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.82 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.82 |
| ▸ | DRD3 | P35462 | 1/20 | 0.82 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.82 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.68 |
| ▸ | MEN1 | O00255 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.68 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.68 |
| ▸ | FDPS | P14324 | 1/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL6944297 | 0.96 | KCNH2 (0.76) | KCNH2CHRM2HTR1AADRA2ACHRM1 | |
| Alverine SCHEMBL5059354 | 0.95 | KCNH2 (0.85) | KCNH2CHRM2HTR1AADRA2ACHRM1 | |
| Alverine SCHEMBL5059400 | 0.93 | KCNH2 (0.82) | KCNH2CHRM2HTR1AADRA2ACHRM1 | |
| Alverine SCHEMBL83067 | 0.91 | KCNH2 (1.00) | KCNH2CHRM2HTR1AADRA2ACHRM1 | |
| Alverine SCHEMBL5061747 | 0.89 | KCNH2 (0.96) | KCNH2CHRM2HTR1AADRA2ACHRM1 | |
| SCHEMBL5711715 | 0.88 | KCNH2 (0.74) | KCNH2CHRM2HTR1AADRA2ACHRM1 | |
| Alverine SCHEMBL5061627 | 0.88 | KCNH2 (0.79) | KCNH2CHRM2HTR1AADRA2ACHRM1 | |
| Alverine SCHEMBL5055922 | 0.88 | KCNH2 (0.79) | KCNH2CHRM2HTR1AADRA2ACHRM1 | |
| Alverine SCHEMBL5054532 | 0.87 | KCNH2 (0.85) | KCNH2CHRM2HTR1AADRA2ACHRM1 | |
| Alverine SCHEMBL2927586 | 0.87 | KCNH2 (0.85) | KCNH2CHRM2HTR1AADRA2ACHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6335368-B1 | ADMINISTERING ALVERINE OR SALT COSMETIC TO SKIN AS MUSCLE RELAXANT; AGING RESISTANCE | SOCIETE L'OREAL S.A. (FR) | 2002-01-01 | — | — | US | claimed |
| CN-101766588-B | Method for preparing stable simethicone/alverine combination | MAYOLY SPINDLER LAB | 2012-11-28 | — | — | CN | disclosed |
| CN-101766588-A | Method for preparing stable simethicone/alverine combination | FRANCE GP PHARMACEUTICAL FACTO | 2010-07-07 | — | — | CN | disclosed |
| US-20080050318-A1 | Use of a combination of components with an inhibitory synergistic effect on calcium channels to prevent or treat wrinkles and fine lines | L'OREAL S.A. | 2008-02-28 | — | — | US | disclosed |
| US-7071167-B2 | For topical application to the skin, cosmetic | L'OREAL (FR) | 2006-07-04 | — | — | US | disclosed |
| US-20040147443-A1 | Use of a combination of components with an inhibitory synergistic effect on calcium channels to prevent or treat winkles and fine lines | L'OREAL S.A. (FR) | 2004-07-29 | — | — | US | disclosed |
| US-6335368-B1 | ADMINISTERING ALVERINE OR SALT COSMETIC TO SKIN AS MUSCLE RELAXANT; AGING RESISTANCE | SOCIETE L'OREAL S.A. (FR) | 2002-01-01 | — | — | US | disclosed |
| JP-2001114676-A | USE OF ALVERINE FOR REDUCING WRINKLE | L'OREAL SA | 2001-04-24 | — | — | JP | disclosed |